The 2025 European Respiratory Society Congress takes place 27 September-1 October in Amsterdam, NL.
Qureight’s strong presence at the event reflects the Company’s mission to advance the understanding of lung and heart disease through its AI-powered data and imaging curation platform, enabling Qureight to build products that accelerate clinical trials, identify new endpoints, and help to bring new treatments to patients faster.
Over the course of the conference, Qureight will take part in eight sessions including two oral presentations and six posters, covering:
• Novel research in Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD), with two studies showing the value of multi-compartment models
• Advancing IPF science with AI and multi-modal data, including an example of imaging aligning with symptomatology in IPF patients, and advancing precision medicine in IPF with a single risk-prediction model
• Collaborations with Vicore Pharma AB, Insilico Medicine and Pulmogene to accelerate new treatments in IPF
• Research on pulmonary arterial hypertension in collaboration with Royal Papworth Hospital NHS Foundation Trust in Cambridge
Dr Simon Walsh, Chief Scientific Officer at Qureight, said: “The ERS Congress brings together global experts to discuss the latest developments in respiratory medicine, and we are excited to have such a strong presence at the event to showcase how our AI-powered imaging and clinical data curation platform is transforming the development of novel therapies for respiratory diseases.”
Confirmed activity at the conference
1. Presentation: Deep learning-based fibrosis and ground glass opacification quantification with proteomic biomarkers for outcome prediction in IPF
• Date: 28th September, 11:00-12:15
• Presenter: Simon Walsh
• Location: 3A
2. Presentation: Deep learning-based airway and vessel volume are associated with increased risk of mortality in CTD-ILD
• Date: 28th September, 11:00-12:15
• Presenter: Simon Walsh
• Location: 3A
3. Poster Discussion: Longitudinal changes in quantitative imaging biomarkers are associated with risk of mortality in CTD-ILD
• Date: 28th September, 08:00-09:30
• Location: Poster Board PS-40
4. Poster Discussion: Deep Learning analysis of serial CT scans correlates with changes in how patients feel, function and survive in fibrotic interstitial lung diseases (Giles Dixon, University of Exeter, Royal United Hospital Bath, North Bristol NHS Trust, Royal Devon University Healthcare)
• Date: 29th September, 08:00-09:30
• Location: Poster Board PS-34
5. Poster Discussion: Synthetic arm generation utilising real-world patient data demonstrates treatment effect in Phase 2a AIR trial of buloxibutid in IPF (Vicore)
• Date: 29th September, 08:00-09:30
• Location: Poster Board PS-37
6. Poster Discussion: Comparison of the baseline clinical and HRCT characteristics of Insilico’s ISM001_055 phase 2a trial cohort in China with real-world IPF datasets (Insilico)
• Date: 30th September, 08:00-09:30
• Location: Poster Board PS-34
7. Poster Discussion: PMG1015 demonstrates well-tolerated safety and favourable FVC changes after 12 weeks of treatment in IPF patients (Pulmogene)
• Date: 30th September, 12:30-14:00
• Location: Poster Board PS-33
8. Poster Discussion: Deep learning-based image quantification of CTPA to phenotype pulmonary arterial hypertension (Hakim Ghani, Royal Papworth Hospital)
• Date: 30th September, 12:30-14:00
• Location: Poster Board PS-37